Torley Helen's Form 4 filing
Halozyme Therapeutics, Inc. (HALO) · filed Feb 21, 2023
- Accession no.
- 0001415889-23-002953
- Filed
- Feb 21, 2023
- Trade date
- Feb 16, 2023
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 3 derivative transactions. Open-market sales total $544.9K. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Torley HelenCIK 0001528185 | Director, Officer (PRESIDENT AND CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 16, 2023 | Common Stock | MOption exerciseAcquired | +21,010 | $0.00 | $0 | 644,727 | Direct | |
| Feb 16, 2023 | Common Stock | SSaleDisposed | −11,061 | $49.26 | −$544,864.86 | 633,666 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 16, 2023 | Common Stock | MOption exerciseDisposed | −21,010 | $0.00 | $0 | 63,027 | Direct | |
| Feb 16, 2023 | Common Stock | AGrant or awardAcquired | +193,360 | $0.00 | $0 | 193,360 | Direct | |
| Feb 16, 2023 | Common Stock | AGrant or awardAcquired | +67,499 | $0.00 | $0 | 67,499 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.